Member, American College of Physicians
One of the goals of Hospital for Special Surgery (HSS) is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.
As part of the disclosure process, this website lists physician collaborations with outside companies if payments were received during the prior year, or if the HSS physician currently receives payment. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.
As of March 03, 2014, Dr. Newman reported no financial interest relationships with healthcare industry.
By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, HSS’ Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.
UMDNJ-Robert Wood Johnson Medical School
North Shore University Hospital
Internal Medicine, 2011
Once-daily application of calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment for repigmentation of facial vitiligo., Newman MD, Silverberg NB. Cutis. 2011 Nov;88(5):256-9.
Therapeutic considerations for severe nodular acne. Newman MD, Bowe WP, Heughebaert C, Shalita AR. Am J Clin Dermatol. 2011 Feb 1;12(1):7-14.
Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients., Nardone B, Nicholson K, Newman M, Guitart J, Gerami P, Talarico N, Yang XJ, Rademaker A, West DP, Lacouture ME. Clin Cancer Res. 2010 Sep 1;16(17):4452-60. Epub 2010 Aug 23.
Sensitivity of fluorescence in situ hybridization for melanoma diagnosis using RREB1, MYB, Cep6, and 11q13 probes in melanoma subtypes., Gerami P, Mafee M, Lurtsbarapa T, Guitart J, Haghighat Z, Newman M., Arch Dermatol. 2010 Mar;146(3):273-8.
The safety of nanosized particles in titanium dioxide- and zinc oxide-based sunscreens., Newman MD, Stotland M, Ellis JI., J Am Acad Dermatol. 2009 Oct;61(4):685-92. Epub 2009 Jul 31.
Distinguishing epithelioid blue nevus from blue nevus-like cutaneous melanoma metastasis using fluorescence in situ hybridization., Pouryazdanparast P, Newman M, Mafee M, Haghighat Z, Guitart J, Gerami P., Am J Surg Pathol. 2009 Sep;33(9):1396-400.
Chromosomal copy number changes supporting the classification of lentiginous junctional melanoma of the elderly as a subtype of melanoma., Newman MD, Mirzabeigi M, Gerami P., Mod Pathol. 2009 Sep;22(9):1258-62. Epub 2009 Jun 19.
Malignant melanoma with monster cells showing massive cyclin D1 amplification., Pouryazdanparast P, Newman M, Mafee M, Guitart J, Gerami P. Am J Dermatopathol. 2009 Jun;31(4):402-3. No abstract available.
Fluorescence in situ hybridization as a tool for microstaging in malignant melanoma., Newman MD, Lertsburapa T, Mirzabeigi M, Mafee M, Guitart J, Gerami P., Mod Pathol. 2009 Aug;22(8):989-95. Epub 2009 May 15.
Palisaded encapsulated neuroma (PEN): an often misdiagnosed neural tumor., Newman MD, Milgraum S., Dermatol Online J. 2008 Jul 15;14(7):12.
For more publications, please see the PubMed listing.
Blood transfusion strategies after hip replacement surgery, 2012
Internal Medicine, Dermatology